他扎罗汀乳膏短时接触疗法治疗寻常痤疮的临床研究

目的 评价0.1%他扎罗汀乳膏短时接触疗法治疗寻常痤疮时能否有效减轻局部不良反应,以及对临床疗效和症状反复的影响.方法 多中心、随机对照方法,将纳入观察的187例寻常痤疮病例分为短时接触疗法8周组,短时接触疗法12周组和常规治疗组.按Doshi痤疮综合分级系统(GAGS)计分评价,观察在治疗开始前(基线期)、完成时以及完成后的第2、4、8周内症状变化情况,评估局部不良反应和疗效,以及对病情反复的影响.结果 短时接触疗法8周组、12周组和常规治疗组局部不良反应率分别为11.48%、12.90%和38.33%,三组比较,差异有统计学意义(X2=13.31,P<0.01).短时接触疗法12周组总有效率(80.65%)较8周组(63.93%)高(X2=3.84,P<0.05).三组总有效率比较,差异无统计学意义(X2=1.98,P>0.05).短时接触疗法12周组能明显降低病情反复,三组间2,4、8周各随访段病情反复率比较,差异均有统计学意义(X2=3.29,3.78和5.85,P<0.05或P<0.01).结论 0.1%他扎罗汀乳膏短时接触疗法治疗寻常痤疮能有效减轻局部不良反应,且不降低疗效;而延长短时接触疗法疗程能减少症状反复,提高疗效.     

0.1%他扎罗汀乳膏短时接触治疗寻常痤疮的疗效观察

［目的］对比观察及评价0.1%他扎罗汀乳膏短时接触治疗与常规每日一次治疗轻中度寻常型痤疮的疗效和安全性。［方法］采用前瞻性开放性对照观察,选用重庆华邦公司0.1%他扎罗汀乳膏局部外用面部轻中度痤疮,短时接触疗法为每晚1次,5分钟后洗去,常规疗法为每晚1次过夜,疗程均为8周,于第1、2、4、8周进行复诊随访。短时接触治疗组为52例,常规治疗组为49例。［结果］第8周时0.1%他扎罗汀短时接触治疗组有效率为69.1%,常规治疗组有效率为75.1%,X2=6.501,P=0.09＞0.05,两组疗效之间无显著统计学差异。不良反应发生率短时接触治疗组为21.2%,常规治疗组为44.9%,X2=8.538,P=0.036＜0.05,两组不良反应发生率有显著统计学差异,短时接触治疗组明显低于常规治疗组。［结论］他扎罗汀短时接触治疗寻常型痤疮安全、有效,值得临床推广应用。     

0．1％他扎罗汀乳膏短时接触疗法治疗面部痤疮疗效观察

目的：观察0．1％他扎罗汀乳膏短时接触疗法治疗轻、中度面部寻常痤疮的临床疗效和安全性。方法：采用随机、单盲及平行对照的临床研究方法分组观察比较0．1％他扎罗汀乳膏短时接触疗法与常规疗法治疗面部痤疮的疗效和安全性。结果：治疗组24例患者外用0．1％他扎罗汀乳膏短时接触疗法后2周、4周和8周的有效率分别为25．0％、41．7％及70．8％，对照组24例患者外用0．1％他扎罗汀乳膏常规疗法疗后2周、4周和8周的有效率分别为20．8％、45．8％及75．0％，两组疗效差异无统计学意义；治疗组与对照组的不良反应发生率分别为4．2％及29．6％，治疗组不良反应发生率显著低于对照组（P〈0．05）。结论：0．1％他扎罗汀乳膏短时接触疗法治疗轻、中度面部寻常痤疮疗效好，不良反应少，有很好的耐受性。     

0.1%他扎罗汀乳膏短时接触隔日维持治疗对寻常痤疮复发的影响

目的:评价0.1%他扎罗汀乳膏短时接触隔日维持治疗对寻常痤疮复发的影响及其安全性.方法:采用多中心、随机、双盲、安慰剂对照方法,对纳入观察的126例经治疗后症状缓解达到Pillsbury分级法属I级以下的寻常痤疮患者.采用0.1%他扎罗汀乳膏(或安慰剂)短时接触隔日维持治疗,按Doshi的痤疮综合分级系统(the global ache grading system,GAGS)计分评价,观察维持疗程第4、8、12周症状变化情况,评估其对症状复发的影响.结果:0.1%他扎罗汀乳膏维持治疗组较安慰剂组的复发率明显降低,在随访的第8和12周复发率差异有统计学意义(χ~2=5.255和8.147,P<0.05);两组无论是轻、中、重度,还是局部不良反应发生率均相近,发生率极低.总的局部不良反应发生率(3.33%/1.69%)比较差异无统计学意义(χ~2=0.325、P>0.05).结论:0.1%他扎罗汀乳膏短时接触隔日维持治疗能减少寻常痤疮复发,且局部不良反应少,具有一定的临床应用价值.     

0.05%他扎罗汀治疗寻常痤疮疗效观察

目的 观察他扎罗汀凝胶治疗寻常痤疮的临床疗效.方法 治疗组70例,外用0.05%他扎罗汀乳膏,每晚1次;对照组45例,外用0.025%维A酸乳膏,每晚1次,均连用8周观察疗效.结果 治疗组有效率68.7%:对照组为49.5%.两组比较差异有统计学意义(P<0.05).结论 0.05%他扎罗汀乳膏治疗寻常痤疮有确切疗效.     

0.1%他扎罗汀凝胶接触治疗寻常痤疮疗效观察

目的：观察0．1％他扎罗汀凝胶短期接触治疗轻、中度面部寻常痤疮的临床疗效和安全性。方法：采用随机、平行对照的临床研究方法，入选病例外涂试验药物，每天2次，疗程12周。结果：治疗组疗后2、4、8、12周的有效率分别为24％、40％、60％、68％；对照组分别为19．2％(P=0．631)、23．1％(P=0．175)、30．8％(P=0．034)、30．8％(P=0．008)。结论：0．1％他扎罗汀凝胶短期接触治疗轻中度面部寻常痤疮疗效好，不良反应轻，有较好的耐受性。     

他扎罗丁乳膏联合润肤霜治疗寻常型银屑病127例疗效观察

目的探讨局部外用他扎罗丁乳膏联合我院自制润肤霜治疗寻常型银屑病的疗效与安全性。方法收集我院皮肤科门诊2016年3月~9月收治的127例寻常型银屑病患者,随机分为2组,治疗组局部外用他扎罗丁乳膏联合我院自制润肤霜于患处,早晚各1次,对照组仅局部外用他扎罗丁乳膏,早晚各1次。均治疗8周后,根据银屑病皮损面积及严重程度指数(PASI)评分下降率进行疗效判定。结果治疗组有效率(84.6%)与对照组有效率(69.4%)相比,差异有统计学意义(P0.05),且无不良反应。结论他扎罗丁乳膏联合我院自制润肤霜治疗寻常型银屑病疗效显著,且无明显不良反应。     

维胺酯胶囊联合夫西地酸钠乳膏治疗寻常性痤疮疗效观察

目的：观察维胺酯胶囊联合夫西地酸钠乳膏治疗寻常性痤疮疗效及不良反应。方法：将396例寻常性痤疮患者随机分为两组。治疗组220例,口服维胺酯联合外用夫西地酸钠乳膏;对照组176例,口服维胺酯联合外用痤疮霜。8周后评价其疗效。结果：治疗组治愈率和总有效率分别为40.91%和89.09%,对照组治愈率和总有效率分别为30.68%和81.25%,治愈率和总有效率两组间比较差异有统计学意义（P〈0.05）。不良反应为局部皮肤轻度潮红,瘙痒,唇干。结论：维胺酯胶囊联合夫西地酸钠乳膏治疗寻常性痤疮疗效显著,不良反应少。     

阿维A胶囊联合他扎罗汀乳膏治疗中重度痤疮52例疗效观察

目的：观察阿维A胶囊联合他扎罗汀乳膏治疗中、重度痤疮的疗效。方法：治疗组口服阿维A胶囊10mg，每天2次，同时皮损外用0.1％他扎罗汀膏，每晚1次；对照组皮损仅外用0.1％他扎罗汀乳膏，每晚1次，两组疗程均8周。结果：治疗组总有效率为90．38％，对照组总有效率为60％，两组比较差异有统计学意义（X^2=11．13，P〈0．01）。结论：阿维A胶囊联合他扎罗汀乳膏治疗中重度痤疮疗效满意。     

红蓝光联合他扎罗汀治疗面部寻常型痤疮60例临床观察

目的评价红蓝光联合他扎罗汀治疗面部寻常型痤疮的临床效果和安全性。方法将入选的179例寻常型痤疮患者随机分为三组,对照1组(60例)予红蓝光治疗,对照2组(59例)予他扎罗汀治疗,治疗组(60例)予红蓝光联合他扎罗汀治疗,比较三组患者的临床疗效和不良反应。疗程均为8周。结果对照1组、对照2组、治疗组的有效率分别为71.67%,79.66%和95.00%。治疗组的有效率均高于其他两组,差异均有统计学意义(P均0.01)。另外,三组患者的不良反应发生率差异无统计学意义(P0.05)。结论红蓝光联合他扎罗汀治疗面部寻常型痤疮疗效好,不良反应轻。     

Efficacy of combined topical treatment of acne vulgaris with adapalene and nadifloxacin: a randomized study

Topical retinoid and antibiotic combination therapy is an integral part of acne treatment and is considered the appropriate first-line therapy according to the Japanese guideline for moderate and severe acne. In this combination, clindamycin or doxycycline are mostly used as antibiotics, but there have been no reports on the effectiveness of nadifloxacin, a widely used antibiotic in Japan and European countries for acne, in combination with topical retinoid. To confirm the efficacy and safety of adapalene gel and nadifloxacin cream in the treatment of Japanese patients with acne vulgaris, a total of 50 patients were randomized to the two groups, the combination therapy and the adapalene monotherapy, and each therapy was tested for 8 weeks. The percentage reduction in the number of inflammatory acne lesions was evaluated and the safety was monitored through adverse events. The combination of adapalene gel and nadifloxacin cream produced a significantly higher reduction in the inflammatory lesions at 2 weeks (P = 0.047) and at 8 weeks (P = 0.011) after the starting than did adapalene gel monotherapy. The combination did not elevate the side effects of erythema and scale scores, but rather significantly depressed erythema at 1 week. This study showed the efficacy and safety of the combination therapy of nadifloxacin cream with adapalene gel for the inflammatory acne.     

自制复方氯硫咪乳膏治疗寻常痤疮临床疗效观察

目的评价复方氯硫咪乳膏治疗寻常痤疮的疗效、依从性、安全性和复发情况。方法采用随机、平行对照的方法,试验组外用复方氯硫咪乳膏,对照组外用0.025%维A酸霜,两组均加服同样内服药物。疗程4w。观察治疗中和疗程结束后的病情变化并记录。结果治疗1w后,试验组基愈率、显效率和有效率均显著优于对照组(P<0.05,P<0.005,P<0.001)。随着疗程增加,两组疗效有趋近倾向。治疗4w后,试验组基愈率和有效率仍高于对照组(P<0.05),但显效率差异无统计学意义(P>0.05),试验组依从指数高于对照组(P<0.001),不良反应的发生率低于对照组(P<0.001)。疗程结束1m后随访,两组复发率无明显差异(P>0.05)。结论复方氯硫咪乳膏治疗寻常痤疮起效快、疗效满意、安全可靠、患者依从性高。     

Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial

New combination topical formulations for the treatment of acne may improve outcomes by increasing adherence. We assessed adherence to and efficacy of a combination topical medication for acne applied once daily compared with daily applications of 2 separate generic subcomponents. Twenty-six participants with mild to moderate acne vulgaris were randomized to 12 weeks of once daily application of clindamycin phosphate 7.2%-tretinoin 0.025% gel (CTG) combination product or separate daily applications of clindamycin phosphate gel 1% and tretinoin cream 0.025% (C gel + T cream) for a total of 2 applications daily. Disease severity was measured at baseline and weeks 4, 8, and 12. Adherence was monitored using electronic monitoring caps on the medication tubes. Of the 26 participants enrolled, 21 completed the 12-week study. Median adherence in the CTG group was 88% compared with 61% in the C gel + T cream group. There was a 51% mean reduction in total lesions for the CTG group versus a 32% mean reduction for the C gel + T cream group by the end of the study. Both CTG and separate applications of C gel + T cream improved mild to moderate acne. The use of a once daily combination product has the advantage of promoting better adherence and clinical outcomes.     

Efficacy and safety of oral silymarin in comparison with oral doxycycline and their combination therapy in the treatment of acne vulgaris

Two factors of oxidative stress and inflammatory processes are implicated in pathogenesis of acne vulgaris. Silymarin has antioxidant and anti‐inflammatory activities. This study was done to evaluate the effect of oral silymarin in the treatment of acne vulgaris compared to doxycycline and also their combination therapy. This randomized controlled trial was performed on 60 patients with acne vulgaris were divided into three groups of 20 patients, including: Silymarin (Group 1), Doxycycline (Group 2), and both compounds (Group 3). The patients' response was monitored every month and the lesions were evaluated using photography and two methods of Global Acne Grading system (GAGS) and Acne Severity Index (ASI). According to the results, the response to silymarin was not significantly different with doxycycline in the GAGS index (p = .260), but was lower in the ASI (p = .021). In this study, the synergistic effects of silymarin and doxycycline combination have been investigated in comparison with doxycycline. Although the improvement was more favorable in combination group, there was no statistically significant difference (p = .9 in ASI and p = .5 in GAGS). The results of our study suggest that although the silymarin monotherapy is not as effective as doxycycline for the treatment of acne vulgaris, it can be a therapeutic option.     

0.1%他扎罗汀乳膏联合罗红霉素治疗痤疮临床观察

目的观察0.1%他扎罗汀乳膏联合罗红霉素治疗痤疮的疗效。方法以0.1%他扎罗汀乳膏外用联合罗红霉素口服作为治疗组,单纯罗红霉素口服作为对照组,观察疗效。结果治疗组有效率优于对照组(P<0.01)。治疗组未见明显不良反应。结论0.1%他扎罗汀乳膏联合罗红霉素治疗痤疮效果好,值得临床推广。     

青年男性寻常痤疮患者膳食生糖负荷水平与皮损严重程度间的相关性研究

目的 通过调查青年男性寻常痤疮患者的膳食生糖负荷水平（GL）,评估其与寻常痤疮皮损严重程度间的相关性,为寻常痤疮综合治疗提供参考。方法 使用痤疮综合分级系统（GAGS）评价患者皮损严重程度。使用食物频率问卷及24 h膳食回顾问卷评估GL水平。方差分析及t检验分析GL及BMI在各组间的差异,并对BMI和GL的影响因素进行Logistic回归分析。结果 99例19 ~ 24岁男性寻常痤疮患者参与本次研究,Logistic回归结果显示,GL是体质指数（BMI）的影响因素,GL越高BMI越容易超标（回归系数β = 1.119,P < 0.05,OR = 3.062,95%置信区间：1.044 ~ 8.986）。未发现GL的影响因素。病程 ＞ 6个月组GL显著高于 ≤ 6个月组（t = 2.947,P < 0.01）;两组间BMI差异无统计学意义（t = 0.798,P > 0.05）。GL在不同GAGS组间差异有统计学意义（F = 76.296,P ＜ 0.01）,≥ 31分组高于19 ~ 30分组（P ＜ 0.01）和1 ~ 18分组（P ＜ 0.01）,19 ~ 30分组高于1 ~ 18分组（P ＜ 0.01）;各组间BMI差异无统计学意义（F = 3.142,P > 0.05）。结论 GL水平与青年男性寻常痤疮患者皮损严重程度及病程正相关。     

Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study

BACKGROUND: Topical retinoids, such as adapalene, are an integral part of acne therapy in most regions and are considered appropriate first-line therapy by international guidelines for all cases of acne with the exception of the most severe. However, there are currently no topical retinoids available for the treatment of acne vulgaris in Japan. OBJECTIVE: To confirm efficacy and safety of adapalene gel 0.1% versus the corresponding gel vehicle in the treatment of Japanese patients with acne vulgaris for up to 12 weeks. METHODS: A total of 200 patients were randomized to receive adapalene gel 0.1%, or vehicle once-daily for 12 weeks. Percent reduction in lesion counts (total, inflammatory, and non-inflammatory) and subject satisfaction were evaluated. Safety was monitored through adverse events and laboratory tests. RESULTS: Adapalene gel 0.1% produced significantly better reductions in total (P<0.0001), inflammatory (P=0.0010), and non-inflammatory lesions (P<0.0001) at endpoint (week 12, last observation carried forward) than gel vehicle, with a higher overall subject satisfaction. The primary efficacy variable, the median percent reduction of total lesion counts at endpoint, was significantly greater with adapalene gel 0.1% (63.2%) compared to that with the vehicle (36.9%) in the ITT population (P<0.0001). Significantly greater results were observed as early as week 1. Adapalene was well tolerated, with adverse events that were mostly mild-to-moderate and transient in nature. CONCLUSIONS: Adapalene gel 0.1% was effective in the treatment of acne vulgaris in Japanese patients. Adapalene was safe and well tolerated, consistent with the good tolerability profile demonstrated in other patient populations.